Dr. Richard M. Bergenstal, MD, executive director of the International Diabetes Center, is an endocrinologist at Park Nicollet Clinic in Minneapolis. He did his medical and endocrine training at the University of Chicago, and has served as a principal investigator in key research studies in type 1 and type 2 diabetes, particularly related to preventing the complications of diabetes. In 2007, he received the ADA's Outstanding Physician Clinician in Diabetes award, among the highest honors in diabetes. He is the president-elect of the American Diabetes Association.
Jennifer Block, RN, CDE is a certified diabetes educator working in pediatric endocrinology at Stanford University. She is currently doing research on the artificial pancreas. Jennifer has type 1 diabetes.
Dr. Zachary Bloomgarden, MD is a professor of medicine at the Mount Sinai School of Medicine in New York City and editor in chief of the Journal of Diabetes. He has contributed to over 150 publications in diabetes-related research and is particularly known for his "Perspectives on the News," a column on new diabetes research findings in Diabetes Care every month.
Dr. Bruce Bode, MD, FACE is a diabetes specialist with Atlanta Diabetes Associates in Atlanta, Georgia. He is very well known for his large, thriving insulin pump practice and his research in this field.
Dr. Nancy Bohannon, MD is a San Francisco-based endocrinologist who specializes in new diabetes drugs and technology in her research and private practice.
Dr. Bruce Buckingham, MD is a professor of pediatrics and endocrinology at Stanford University. He is known for his research with DirecNET in particular and his research on continuous monitoring and the artificial pancreas.
Dr. John Buse, MD, PhD is a professor at the University of North Carolina School of Medicine in Chapel Hill, North Carolina and a past President, Medicine & Science at the American Diabetes Association. He serves as the Chief of the Division of Endocrinology, Director of the Diabetes Care Center, and Executive Associate Dean for Clinical Research. Dr. Buse has extensively researched type 1 and type 2 diabetes, including involvement with the ACCORD, GRADE STOPP-T2D, NAVIGATOR, ORIGIN, IRIS, TECOS, FREEDOM and Trialnet trials. Dr. Buse has received a number of awards, including recognition as one of the Best Doctors in America since 2001.
Dr. Wayman W. Cheatham, MD, FACE is the Special Assistant to the Surgeon General for Clinical Research and Director, Clinical Investigation Programs in Washington, D.C. He has been responsible for many large clinical trials in the areas of diabetes and obesity over the course of his career and has extensive experience in drug development. Dr. Cheatham has type 2 diabetes.
Dr. Edward Damiano, PhD is an Associate Professor of Biomedical Engineering at Boston University. His expertise and training are in the areas of mechanical and biomedical engineering, applied mechanics, and applied mathematics. Ever since his 14-year-old son was diagnosed with type 1 diabetes at 11 months of age, he has been committed to creating and integrating closed-loop control technologies with a vision of building a bionic endocrine pancreas by the time his son heads off to college in the fall of 2017.
Dr. J. Hans DeVries is an internist and endocrinologist at the Academic Medical Centre in Amsterdam. His PhD thesis (2003) focused on subcutaneous and intraperitoneal insulin delivery in type 1 diabetes. He has published, with his PhD students, over 100 publications listed. He is an editorial board member of a range of academic journals and his research interests are many, including insulin therapies, continuous glucose monitoring, the artificial pancreas, and glycemic control in hospitalized patients. He is the scientific coordinator of the renowned AP@home, a consortium attempting to close the loop.
Dr. Michael Dougan, MD, PhD is an internal medicine resident at Massachusetts General Hospital with a longstanding interest in science education. He received his MD and PhD from Harvard Medical School, where his research focused on immune modulation and chronic inflammation.
Dr. Steve Edelman, MD is a professor of Medicine in the Division of Endocrinology and Metabolism at the University of California, San Diego. He is Director of the Diabetes Care Clinic at the Veterans Affairs Medical Center in San Diego as well as the founder and director of Taking Control of Your Diabetes (TCOYD). In 2009, he was named Educator of the Year at the American Diabetes Association Scientific Sessions.
Dr. Satish K. Garg, MD is a Professor of Medicine and Pediatrics at the Young Adult Clinic at the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine at the Anschutz Medical Campus, in Aurora, Colorado and the Editor-In-Chief of Diabetes Technology and Therapeutics Journal. He is a prolific researcher with over 170 original manuscripts in peer-review journals and is considered a leading expert in early detection of diabetes, treatment of renal and retinal complications of type 1 diabetes, and multiple diagnostic and therapeutic tools and therapies, including insulin analogs and glucose sensors in particular.
Dr. James R. Gavin III, M.D., Ph.D is a Professor of Medicine at the Emory University School of Medicine and a Clinical Professor of Medicine at the Indiana University School of Medicine. Additionally, he was the President of the Morehouse School of Medicine from 2002-2004. He is the Chief Medical Officer and Chief Executive Officer of Healing our Village, a health communication corporation that specializes in targeted advocacy, training, education, and outreach for health care professionals and minority communities. He has published more than 200 articles and abstracts in such publications as Science, Journal of Applied Physiology, Diabetes, and the American Journal of Physiology.
Dr. Barry H. Ginsberg, MD, PhD is the CEO of Diabetes Technology Consultants and a former vice president in the diabetes division at BD. He is an expert in blood glucose monitoring and drug delivery.
Dr. Barry J. Goldstein, MD, PhD, FACE has over 25 years of experience in diabetes in clinical and basic R&D in academia and industry. He is Vice President and Global Therapeutic Area Head for Cardiovascular, Metabolic, Diabetes, Endocrinology and Renal disease, at Covance, Inc. Dr. Goldstein received his MD/PhD degrees from the University of Rochester, completed research and clinical fellowships at the Joslin Diabetes Center and Brigham and Women's Hospital, and spent 16 years as Professor and Division Chief for Endocrinology and Diabetes at Jefferson Medical College. Prior to joining Covance, he served at Merck Research Laboratories as VP and TA Area Head for Diabetes & Endocrinology. Dr. Goldstein is an elected member of the ASCI and AAP, a past Associate Editor of Diabetes and the Journal of Clinical Endocrinology and Metabolism, and has served on grant review panels for NIH, ADA, JDRF, and industry scientific advisory panels. His contributions to the literature include more than 220 papers, editorals, monographs, book chapters and co-editorships.
Jeff Halpern is a strategic consumer marketer with over 20 years of experience in marketing consumer packaged goods, high technology, and medical devices. Most recently, Jeff managed the Glad Food Storage brand at The Clorox Company. Jeff has type 1 diabetes.
Dr. Lutz Heinemann, MD is the CEO of Profil Institute for Metabolic Research in Neuss, Germany. He is involved in numerous studies with patients with type 1 and type 2 diabetes and is viewed as an expert in diabetes technology in particular.
Debbie Hinnen, MN, ARNP, BC-ADM, CDE, FAAN is a noted diabetes educator from Kansas with the Mid-America Diabetes Associates. She has served as the president of the American Association of Diabetes Educators and is involved with much new product development.
Dr. Irl Hirsch, MD is a professor of medicine in the division of Metabolism, Endocrinology, and Nutrition at the University of Washington. He is well known for his research on insulin and glycemic variability, among other topics. Dr. Hirsch has type 1 diabetes.
Jeff Hitchcock is the founder of Children with Diabetes, one of the largest diabetes-related web sites in the world. He is particularly inspired by his daughter Marissa, who has type 1 diabetes, and is currently studying to be a Certified Diabetes Educator.
Dr. Philip Home, MA, DPhil, DM, FRCP trained in medicine at Oxford University and now teaches and is now Professor of Diabetes Medicine at Newcastle upon Tyne, England. He practiced in diabetes care and disorders of lipid metabolism at the Newcastle Diabetes Centre and at the Newcastle Hospitals until 2011 and is now engaged in research full time. He has published over 390 papers, books and reviews on aspects of diabetes. Professor Home was Editor of Diabetic Medicine and active on many medical editorial boards. Professor Home has been extremely active in IDF, in multiple diabetes boards in the UK and has assisted in diabetes developments in countries, including China, Paraguay, Malta, Russia, India, the Philippines, Pakistan, and New Zealand.
Dr. Lois Jovanovic, MD, FACE is the Director of the Sansum Diabetes Research Institute in Santa Barbara, California. Her research has focused on pregnancy and diabetes and she is widely considered the foremost expert in the world on this topic. Dr. Jovanovic has type 1 diabetes.
Dr. Francine Kaufman, MD is the head of the Division of Endocrinology and Metabolism at the Children's Hospital in Los Angeles and a pediatric endocrinologist at the University of Southern California. She is a former president of the American Diabetes Association and the medical director at a summer camp for children with diabetes.
Dr. David M. Kendall, MD is the Chief Scientific and Medical Officer of the American Diabetes Association. Prior to his appointment to the ADA, he was the Medical Director and Chief of Clinical and Professional Services at the International Diabetes Center in Minneapolis, MN. An active diabetes researcher, educator and clinician, Dr. Kendall has both clinical and laboratory based research interests. His clinical studies focus on the prevention and treatment of cardiovascular complications of diabetes while his laboratory research centers on emerging treatments for diabetes, insulin resistance, and the metabolic syndrome. He is particularly well known for his research on emerging incretin-based therapies for type 2 diabetes.
Dr. Boris Kovatchev, PhD is Professor in the Department of Psychiatry and Neurobehavioral Sciences and Adjunct Professor of Systems and Information Engineering, University of Virginia. Charlottesville, Virginia, Head of Section Computational Neuroscience, and Director of the University of Virginia Center for Diabetes Technology. He received Ph.D. in Mathematics (Probability and Statistics) from Sofia University “St. Kliment Ohridski,” Bulgaria. Kovatchev has a 18-year track record in translational diabetes research and is the recipient of the Diabetes Technology Leadership Award for 2008. He is the author of 123 peer-reviewed scientific publications, and holds 36 U.S. and international patents and 62 patents currently pending. In 2011 he was named UVA Edlich-Henderson Inventor of the Year.
Dr. Aaron Kowalski, PhD is the Director of Strategic Research Projects of the Juvenile Diabetes Research Fund, an organization dedicated to finding a cure for diabetes. He leads the efforts of the Artificial Pancreas Project at JDRF. Dr. Kowalski has type 1 diabetes.
Davida F. Kruger, MSN, APN-BC, BC-ADM has worked over 30 years as certified nurse practitioner in diabetes research and clinical practice at Henry Ford Health System/Detroit, Michigan. Ms. Kruger has served as past Chair of the American Diabetes Associations (ADA) Research Foundation, and past President of Health Care and Education of the ADA. She is presently the Editor-In-Chief of Clinical Diabetes was previously editor of Diabetes Spectrum. A principal investigator on numerous diabetes care research projects, she is widely published including authoring the book The Diabetes Travel Guide and has been honored by numerous awards including The ADA Wendell May’s Award.
Dr. Harold Lebovitz, MD is Professor of Medicine in the Division of Endocrinology and Metabolism at the State University of New York (SUNY) Health Science Center at Brooklyn. He has served on numerous review committees for the American Diabetes Association, the National Institutes of Health, and the Veterans Administration, and serves on the editorial boards of Diabetes, Obesity and Metabolism, and Diabetes Care.
Dr. Anne Peters, MD is a Professor of Medicine at the Keck School of Medicine of USC, Director of the USC Westside Center for Diabetes, and Director of the Comprehensive Diabetes Center at Roybal Community Medical Center. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago, completed an internal medicine internship at Stanford University, and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes programs at Cedars-Sinai and UCLA. She has published numerous articles and serves on the editorial board of several journals.
Dr. William H. Polonsky, PhD, CDE is a professor of psychiatry at the University of California San Diego and the founder of the Behavioral Diabetes Institute, an organization focusing on the psychological aspects of diabetes.
Michael Robinton is the founder and Executive Director of Insulin Pumpers (www.insulin-pumpers.org), a large online forum for pump users.
Dr. Francesco Rubino, MD is the Chief of Gastrointestinal Metabolic Surgery, an Associate Professor of Surgery, and an Associate Attending Surgeon at New York-Presbyterian/Weill Cornell Medical Center. Dr. Rubino is a pioneer in the emerging field of surgery for type 2 diabetes. He leads the Diabetes Surgery Center at the New York-Presbyterian/Weill Cornell Medical Center, the first academic-based diabetes surgery center in the United States, and is considered the leading expert in surgery for type 2 diabetes. Dr. Rubino is the author of more than 70 articles in peer-reviewed journals and 20 book chapters.
Dr. Steven Jon Russell, MD, PhD is an Assistant Professor of Medicine at Harvard Medical School and an Attending Physician at Massachusetts General Hospital. Dr. Russell earned his MD and PhD at University of Texas Southwestern Medical School and did his residency and fellowship at Massachusetts General Hospital. He is certified in Internal Medicine and Endocrinology, Diabetes, and Metabolism. Dr. Russell is a principal investigator in a collaborative group of investigators from Massachusetts General Hospital and Boston University who are working to make automated blood glucose control a reality. He is active in a number of professional societies and is a reviewer for several journals including The New England Journal of Medicine, Diabetes, and Diabetes Care.
Dr. Jane Jeffrie Seley, NP, CDE is a nurse practitioner and diabetes educator on the Diabetes Team at New York Presbyterian-Weill Cornell Medical Center in New York City. She holds several leadership roles in the New York City chapters of ADA and AADE.
Dr. Arya Sharma, M.D., Ph.D is a Professor of Medicine & Chair in Obesity Research and Management at the University of Alberta, Edmonton, Canada. He is also the Clinical Co-Chair of the Alberta Health Services Obesity Program. Dr. Sharma is founder and Scientific Director of the Canadian Obesity Network, a network of over 6000 obesity researchers, health professionals and other stakeholders. He has authored and co-authored more than 300 scientific articles and has lectured widely on the etiology and management of obesity and related cardiovascular disorders. He is the Past-President of the Canadian Association of Bariatric Physicians and Surgeons
Dr. Jay Skyler, MD is Professor, Division of Endocrinology, Diabetes, and Metabolism and Associate Director of the Diabetes Research Institute at the University of Miami Miller School of Medicine. Dr. Skyler's research interests are in the clinical aspects of diabetes, particularly improving the care of type 1 diabetes through glycemic control, psychosocial and behavioral support, immune intervention and beta cell expansion. He is a past President of the American Diabetes Association.
Virginia Valentine, CNS, BC-ADM, CDE is the CEO of Diabetes Network in New Mexico and the 2006 recipient of the American Association of Diabetes Educators Distinguished Service Award. Virginia has type 2 diabetes.
Dr. Robert A. Vigersky, MD is the Director of the Diabetes Institute of the Walter Reed National Military Medical Center in Bethesda, Maryland and Professor of Medicine at the Uniformed Services University of the Health Sciences. He trained in Internal Medicine at The Johns Hopkins Hospital completed an Endocrine Fellowship at National Institutes of Health. Between stints in the Army, he spent 15 years in private practice and served as the Medical Director of the Diabetes Treatment Center at Georgetown University Hospital and the Washington Hospital Center. He has received numerous military awards and represents the Department of Defense on the Advisory Council of the NIDDK. He was the recipient of the Leadership Award of the Diabetes Technology Society in 2011 and the Thurman Award for Excellence in Telemedicine and Advanced Technology in 2012. He has over 120 publications in the fields of reproductive endocrinology and diabetes.
Dr. W. Kenneth Ward, MD is an associate professor of endocrinology and diabetes at the Oregon Health and Science University and was the former Chief Scientific Officer of iSense, a company recently acquired by Bayer that is focused on the development of continuous glucose monitoring devices. With over 60 publications in peer-reviewed journals, Dr. Ward is well known for his work on glucose sensors and the artificial pancreas. Most recently, Dr. Ward and his colleagues became the first group ever to publish work on the use of both insulin and glucagon, another important hormone involved in regulating blood glucose levels, in a closed loop system in individuals with type 1 diabetes.
Hope Warshaw, MMSc, RD, CDE, BC-ADM, is a diabetes nutrition consultant, freelance writer and diabetes educator in Northern Virginia. She’s the author of several books published by ADA and currently serves on AADE’s Board of Directors.
Dr. Howard Wolpert, MD is the director of the Insulin Pump Program and a clinical investigator at the Joslin Diabetes Center in Boston as well as an instructor of medicine at Harvard Medical School.
Dr. Mark Yarchoan, MD is an internal medicine resident at the University of Pennsylvania with an interest in diabetes care and metabolic disease. He has been a long-standing contributor and editor of diaTribe and has reported on numerous diabetes and obesity conferences. He recently graduated from the University of Pennsylvania Perelman School of Medicine.
Gloria Yee, RN, CDE is a certified diabetes educator at the Diabetes Teaching Center at the University of California San Francisco. Her research focuses on diabetes technology. Gloria has type 1 diabetes.
Professor Paul Zimmet, MD is a Professor of Medicine at Monash University and a director at the International Diabetes Institute both in Melbourne, Australia. The "Endo of Oz" is also co-Chair of the IDF Task Force on Epidemiology. He also serves on the Australian Government's Strategic Taskforce on Diabetes.
Dr. Bernie Zinman, MD is the Director of the Leadership Sinai Center for Diabetes at Mount Sinai Hospital and the University of Toronto, Canada, where he is also a Professor of Medicine. His main research interests include the long-term complications of diabetes, the development of new therapies for type 1 and type 2 diabetes, diabetes in Aboriginal communities, and studies directed at the prevention of diabetes.
Dr. Howard Zisser, MD is the Director of Clinical Research and Diabetes Technology at Sansum Diabetes Research Institute in Santa Barbara, California and serves Adjunct Professor of Chemical Engineering at the University of California, Santa Barbara. His research interests focus on the testing of new drugs and devices to treat diabetes. He has directed numerous clinical trials and investigator-initiated studies involving type 1, type 2, and gestational diabetes, including pivotal testing of implanted glucose sensors, implanted insulin pumps, inhaled insulin, oral insulin, and continuous glucose sensing in pregnancy.